Human TNF receptor fusion protein

US8063182B1 · kind B1 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Manfred Brockhaus · Bettingen, CH
• Reiner Gentz · Silver Spring, US
• Dembic Zlatko · Basel, CH
• Werner Lesslauer · Riehen, CH
• Hansruedi Lotscher · Möhlin, CH
• Ernst-Jurgen Schlaeger · Weil am Rhein, DE

Key dates

• Filing date: May 19, 1995
• Grant date: Nov 22, 2011
• Expiry date: May 19, 2015

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S930/144
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is concerned with non-soluble proteins and soluble or insoluble fragments thereof, which bind TNF, in homogeneous form, as well as their physiologically compatible salts, especially those proteins having a molecular weight of about 55 or 75 kD (non-reducing SDS-PAGE conditions), a process for the isolation of such proteins, antibodies against such proteins, DNA sequences which code for non-soluble proteins and soluble or non-soluble fragments thereof, which bind TNF, as well as those which code for proteins comprising partly of a soluble fragment, which binds TNF, and partly of all domains except the first of the constant region of the heavy chain of human immunoglobulins and the recombinant proteins coded thereby as well as a process for their manufacture using transformed pro- and eukaryotic host cells.